Author: Penghui Yang; Yibo Ding; Zhe Xu; Rui Pu; Ping Li; Jin Yan; Jiluo Liu; Fanping Meng; Lei Huang; Lei Shi; Tianjun Jiang; Enqiang Qin; Min Zhao; Dawei Zhang; Peng Zhao; Lingxiang Yu; Zhaohai Wang; Zhixian Hong; Zhaohui Xiao; Qing Xi; Dexi Zhao; Peng Yu; Caizhong Zhu; Zhu Chen; Shaogeng Zhang; Junsheng Ji; Guangwen Cao; Fusheng Wang
Title: Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China Document date: 2020_3_3
ID: 2vdvswda_36
Snippet: It is critical to identify COVID-19 patients who are most likely to have poor outcomes so that prevention and treatment efforts can be focused. 24 Here, we reported that serum IL-6 and lactate at the admission independently predicted poor outcomes of COVID-19 patients, after the adjustment with other significant factors in the univariate Cox analysis (Table 3) . IL-6 is capable of inhibiting the T cell-mediated immunity, and high level of IL-6 in.....
Document: It is critical to identify COVID-19 patients who are most likely to have poor outcomes so that prevention and treatment efforts can be focused. 24 Here, we reported that serum IL-6 and lactate at the admission independently predicted poor outcomes of COVID-19 patients, after the adjustment with other significant factors in the univariate Cox analysis (Table 3) . IL-6 is capable of inhibiting the T cell-mediated immunity, and high level of IL-6 in the acute stage is associated with lung lesions in SARS patients. 25 Lactate is a natural by-product of aerobic glycolysis. Efferocytosis can promote glucose uptake and lactate release. 26 Lactate promotes the switch of CD4 + T cells to an IL-17 + subset and impairs the cytolytic capacity of CD8 + T cells. 27 Thus, IL-6 might bridge SARS-CoV-2 infection and alveolar cell injury via inducing . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- acute stage and high level: 1, 2, 3
- admission lactate and Cox analysis: 1, 2, 3, 4, 5, 6, 7
- admission lactate and high level: 1, 2
- aerobic glycolysis and glucose uptake: 1, 2
- aerobic glycolysis and lactate release: 1
- alveolar cell injury and cell injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- cc NC ND International license and cell injury: 1, 2, 3
- cc NC ND International license and cell mediate: 1, 2
- cc NC ND International license and glucose uptake: 1
- cc NC ND International license and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cell injury and Cox analysis: 1
- cell injury and high level: 1, 2, 3
- cell injury and International license: 1, 2, 3
- cell injury and lactate release: 1
- cell mediate and high level: 1, 2
- cell mediate and International license: 1, 2, 3
- Cox analysis and glucose uptake: 1
- Cox analysis and high level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Co phrase search for related documents, hyperlinks ordered by date